Access Restriction

Author Dosaka-akita, H. ♦ Yamazaki, K. ♦ Izumi, H. ♦ Itoh, T. ♦ Katoh, H. ♦ Nishimura, M. ♦ Matsuo, K. ♦ Yamada, Y. ♦ Kohno, K. ♦ Kinoshita, I.
Source PubMed Central
Content type Text
Publisher Nature Publishing Group
File Format PDF
Date Created 2002-09-18
Copyright Year ©2002
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health ♦ Diseases
Subject Keyword Cancer Research ♦ Oncology
Abstract N-acetylgalactosaminyl transferase-3 (GalNAc-T3) is an enzyme involved in the initial glycosylation of mucin-type O-linked proteins. In the present study, we used immunohistochemistry to examine GalNAc-T3 expression in 215 surgically resected non-small cell lung cancers. We analysed the biological and clinical importance of GalNAc-T3 expression, especially with regard to its potential as a prognostic factor. We found that normal bronchial epithelial cells, bronchial gland cells, and alveolar pneumocytes showed cytoplasmic immunostaining for GalNAc-T3. Low expression of GalNAc-T3, observed in 93 of 215 tumours (43.4%), was found more frequently in tumours from smokers than those from nonsmokers (P=0.001), in squamous cell carcinomas than nonsquamous cell carcinomas (P<0.0001), and in moderately and poorly differentiated tumours than well differentiated tumours (P=0.0002). Multivariate logistic regression analysis showed that an association of low GalNAc-T3 expression with squamous cell carcinomas was the only one significant relationship of GalNAc-T3 expression with various factors (P<0.0001). Moreover, tumours losing GalNAc-T3 expression had a significantly higher Ki-67 labelling index than tumours retaining GalNAc-T3 expression (P=0.0003). Patients with low GalNAc-T3 expression survived a significantly shorter time than patients with high GalNAc-T3 expression in 103 pStage I non-small cell lung cancers (5-year survival rates, 58% and 78%, respectively; P=0.02 by log-rank test) as well as in 61 pStage I nonsquamous cell carcinomas (5-year survival rates, 63% and 85%, respectively; P=0.03). Low GalNAc-T3 expression was an unfavourable prognostic factor in pStage I non-small cell lung cancers (hazards ratio, 2.04; P=0.03), and in pStage I nonsquamous cell carcinomas (hazards ratio, 2.70; P=0.03). These results suggest that GalNAc-T3 is a new marker of non-small cell lung cancers with specificity for histology and prognosis.
ISSN 00070920
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2002-09-23
Rights Holder Nature Publishing Group
e-ISSN 15321827
Journal British Journal of Cancer
Volume Number 87
Issue Number 7
Page Count 5
Starting Page 751
Ending Page 755

Open content in new tab

   Open content in new tab
Source: PubMed Central